The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
Open accessAbstract
Objectives The purpose of this study was to estimate the effect of long-term exposure to lower plasma low-density lipoprotein cholesterol (LDL-C) on the risk of coronary heart disease (CHD).Background LDL-C is causally related to the risk of CHD. However, the association between long-term exposure to lower LDL-C beginning early in life and the risk of CHD has not been reliably quantified.Methods We conducted a series of meta-analyses to estimate the effect of long-term exposure to lower LDL-C on the risk of CHD mediated by 9 polymorphisms in 6 different genes. We then combined these Mendelian randomization studies in a meta-analysis to obtain a more precise estimate of the effect of long-term exposure to lower LDL-C and compared it with the clinical benefit associated with the same magnitude of LDL-C reduction during treatment with a statin.Results All 9 polymorphisms were associated with a highly consistent reduction in the risk of CHD per unit lower LDL-C, with no evidence of heterogeneity of effect (I(2) = 0.0%). In a meta-analysis combining nonoverlapping data from 312,321 participants, naturally random allocation to long-term exposure to lower LDL-C was associated with a 54.5% (95% confidence interval: 48.8% to 59.5%) reduction in the risk of CHD for each mmol/l (38.7 mg/dl) lower LDL-C. This represents a 3-fold greater reduction in the risk of CHD per unit lower LDL-C than that observed during treatment with a statin started later in life (p = 8.43 × 10(-19)).Conclusions Prolonged exposure to lower LDL-C beginning early in life is associated with a substantially greater reduction in the risk of CHD than the current practice of lowering LDL-C beginning later in life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, genetic variants reflect the effect of lifelong changes in ApoB-containing lipoproteins on the risk of cardiovascular disease, which appear to be cumulative over time.5,34”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredIn the citing paper
“Numerous epidemiological studies, Mendelian randomization studies, and RCTs have consistently demonstrated a log-linear relationship between the absolute changes in plasma LDL-C and the risk of ASCVD [34,45-50].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [47]
In the citing paper
“Additionally, increasing evidence also suggests that the duration of exposure to low LDL-C levels may be as important as the magnitude of LDL-C lowering [11][12][13][14][15][16].”
In the citing paper
“A large meta-analysis by Ference et al. has demonstrated that prolonged exposure to lower LDL-C levels beginning at a young age is associated with a substantially greater reduction in the risk of CVD than the current practice of lowering LDL-C levels later in life [13].”
In the citing paper
“It was found that lifelong exposure to low LDL-C levels as a result of these gene polymorphisms was associated with three-fold greater reduction in the risk of CVD per unit lower LDL-C level than that observed during treatment with a statin started later in life.”
In the citing paper
“The long-term follow-up of large clinical trials of statins that were conducted in the 1990s, such as the West of Scotland Coronary Prevention Study (WOSCOPS) and the Heart Protection Study (HPS)628, 629) confirmed that early initiation of LDLC-lowering therapy regardless of the plasma LDL-C level was useful for the long-term prevention of cardiovascular events and all-cause mortality in high-risk”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [628]
In the citing paper
“No increases in new-incidence cancer or non-CVD deaths were observed, which reconfirms the safety of long-term LDL-C-lowering therapy using statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [628]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
The International Consortium for Blood Pressure Genome-Wide Association Studies (2011) · Nature · doi:10.1038/nature10405 · Cited by 2,033
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics · doi:10.1038/ng.784 · Cited by 1,866
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 901
Niiranen, T., & Vasan, R. S. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1176528 · Cited by 49
Walker, V. M., Zheng, J., Gaunt, T. R., & Smith, G. D. (2022) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-122120-024910 · Cited by 44
Ademi, Z., Norman, R., Pang, J., Sijbrands, E., Watts, G., Hutten, B., & Wiegman, A. (2023) · JAMA pediatrics · doi:10.1001/jamapediatrics.2023.0763 · Cited by 39
Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application
Pang, J., SULLIVAN, D. R., Brett, T., Kostner, K., Hare, D. L., & Watts, G. F. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.12.002 · Cited by 48
Khanicheh, E., Qi, Y., Xie, A., Mitterhuber, M., Xu, L., Mochizuki, M., Daali, Y., Jaquet, V., Krause, K. H., Ruggeri, Z. M., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301710 · Cited by 44
Saborowski, M., Dölle, M., Manns, M. P., Leitolf, H., & Zender, S. (2017) · Cardiology Journal · doi:10.5603/cj.a2017.0137 · Cited by 46
Sinning, D., & Landmesser, U. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01427-6 · Cited by 44
Mendelian Randomization Estimates May Be Inflated
Schooling, C. M., Yeung, S. L. A., & Freeman, G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.049 · Cited by 44
Ip, C.-K., Jin, D.-M., Gao, J.-J., Meng, Z., Meng, J., Tan, Z., Wang, J.-F., & Geng, D.-F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.228 · Cited by 43
Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study
Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy060 · Cited by 44
Liu, Y., Liu, F., Zhang, L., Li, J., Kang, W., Mingli, C., Song, F., & Song, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-01738-w · Cited by 43
Návar, A. M., Fine, L. J., Ambrosius, W. T., Brown, A. F., Douglas, P. S., Johnson, K., Khera, A. V., Lloyd‐Jones, D. M., Michos, E. D., Mujahid, M. S., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100430 · Cited by 42
Millwood, I. Y., Bennett, D., Walters, R. G., Clarke, R., Waterworth, D. M., Johnson, T., Chen, Y., Yang, L., Yu, C., Bian, Z., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw087 · Cited by 43
Dempsey, P. C., Musicha, C., Rowlands, A. V., Davies, M. J., Khunti, K., Razieh, C., Timmins, I. R., Zaccardi, F., Codd, V., Nelson, C. P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03323-x · Cited by 47
Burger, P. M., Dorresteijn, J. A. N., Koudstaal, S., Holtrop, J., Kastelein, J. J. P., Jukema, J. W., Ridker, P. M., Mosterd, A., & Visseren, F. L. J. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118540 · Cited by 52
Rallidis, L. S., Triantafyllis, A. S., Tsirebolos, G., Katsaras, D. N., Rallidi, M., Moutsatsou, P., & Lekakis, J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.023 · Cited by 42
Casula, M., Olmastroni, E., Boccalari, M. T., Tragni, E., Pirillo, A., & Catapano, A. L. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.021 · Cited by 44
Wang, Q., Wang, Y., Lehto, K., Pedersen, N. L., Williams, D. M., & Hägg, S. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.007 · Cited by 42
Inferring Causal Relationships between Risk Factors and Outcomes Using Genetic Variation
Burgess, S., Foley, C. N., & Zuber, V. (2019) · Wiley eBooks · doi:10.1002/9781119487845.ch23 · Cited by 40
Kawamoto, R., Kikuchi, A., Akase, T., Ninomiya, D., & Kumagi, T. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01533-6 · Cited by 39
Smith, M. L., Bull, C. J., Holmes, M. V., Smith, G. D., Sanderson, E. C. M., Anderson, E. L., & Bell, J. A. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104503 · Cited by 40
The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease
Ference, B. A., & Mahajan, N. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0312-1 · Cited by 41
Self-citationGenetic variants in CETP increase risk of intracerebral hemorrhage
Anderson, C. D., Falcone, G. J., Phuah, C., Radmanesh, F., Brouwers, H. B., Battey, T. W. K., Biffi, A., Peloso, G. M., Liu, D. J., Ayres, A. M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24780 · Cited by 40
Zheng, S., Zhu, W., Shi, Q., Wang, M., Nie, Y., Zhang, D., Cheng, Z., Yin, C., Miao, Q., Luo, Y., et al. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.145046 · Cited by 42
How to live to 100 before developing clinical coronary artery disease: a suggestion
D, E. B. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab532 · Cited by 40
McCormack, T., Dent, R., & Blagden, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12881 · Cited by 39
Williams, K. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320065 · Cited by 41
Self-citationMetabolomics in epidemiology: from metabolite concentrations to integrative reaction networks
Fearnley, L. G., & Inouye, M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw046 · Cited by 41
The emerging concept of “individualized cholesterol-lowering therapy”: A change in paradigm
Lütjohann, D., Stellaard, F., Mulder, M. T., Sijbrands, E. J. G., & Weingärtner, O. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.004 · Cited by 41
Carter, P., Vithayathil, M. K., Kar, S., Potluri, R., Mason, A. M., Larsson, S. C., & Burgess, S. (2020) · eLife · doi:10.7554/elife.57191 · Cited by 38
Agbaje, A. O., Lloyd‐Jones, D. M., Magnussen, C. G., & Tuomainen, T. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.11.011 · Cited by 38
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia
Verbeek, R., Stoekenbroek, R. M., & Hovingh, G. K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.099 · Cited by 39
Catapano, A. L., Lautsch, D., Tokgözoğlu, L. S., Ferrières, J., Horack, M., Farnier, M., Toth, P. P., Brudi, P., Tomassini, J. E., Ambegaonkar, B. M., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.007 · Cited by 37
Alirocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305354 · Cited by 37
Leipold, R. J., Raal, F. J., Ishak, J., Hovingh, K., & Phillips, H. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317730473 · Cited by 37
Laitinen, T. T., Nuotio, J., Juonala, M., Niinikoski, H., Rovio, S., Viikari, J. S. A., Rönnemaa, T., Magnussen, C. G., Jokinen, E. V., Lagström, H., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0869 · Cited by 37
Xue, H., & Pan, W. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1009105 · Cited by 37
The Hong Kong Diabetes Register TRS Study Group, Tam, C. H. T., The Hong Kong Diabetes Biobank Study Group, Lim, C. K. P., Luk, A. O. Y., Ng, A. C. W., Lee, H. M., Jiang, G., Lau, E. S. H., Fan, B., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00831-z · Cited by 37
Jia, Y., Liu, J., Guo, Y., Xu, R., Sun, J., & Li, J. (2013) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1671-5411.2013.04.007 · Cited by 37
Marquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00936-0 · Cited by 34
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs
Lincoff, A. M., Ray, K. K., Sasiela, W. J., Haddad, T. M., Nicholls, S. J., Li, N., Cho, L., Mason, D., Libby, P., Goodman, S. G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.048 · Cited by 44
Recent advances in the pharmacological management of hypercholesterolaemia
Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 36
Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study
Gavina, C., Araujo, F. P., Teixeira, C. A. C., Ruivo, J., Corte-Real, A. L., Duarte, L. L., Canelas‐Pais, M., & Taveira‐Gomes, T. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.017 · Cited by 36
Bohula, E. A., Marston, N., Ruzza, A., Murphy, S. A., Ferrari, G. M. D., Díaz, R., Leiter, L. A., Elliott‐Davey, M., Wang, H., Bhatia, A. K., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.12.004 · Cited by 36
Cardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia
Bosco, G., Mszar, R., Piro, S., Sabouret, P. F., & Gallo, A. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01225-3 · Cited by 39
Targeting LDL: Is lower better and is it safe?
Stein, E. A., & Raal, F. J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.010 · Cited by 35
Dyslipidemias in clinical practice
Cabezas, M. C., Burggraaf, B., & Klop, B. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.09.010 · Cited by 36
Mendelian Randomization in Cardiovascular Research
Bell, K., Loy, C. T., Cust, A. E., & Teixeira-Pinto, A. M. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.005623 · Cited by 35
The emerging landscape of peptide-based inhibitors of PCSK9
Tombling, B. J., Zhang, Y., Huang, Y., Craik, D. J., & Wang, C. K. L. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.903 · Cited by 34
Pediatric Lipid Screening Prevalence Using Nationwide Electronic Medical Records
Thompson‐Paul, A. M., Kraus, E. M., Porter, R. M., Pierce, S. L., Kompaniyets, L., Sekkarie, A., Goodman, A. B., & Jackson, S. L. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21724 · Cited by 34
Enas, E. A., Kuruvila, A. T., Khanna, P., Pitchumoni, C. S., & Mohan, V. (2013) · Europe PMC (PubMed Central) · Cited by 34
Lv, H., Jin, D., Liu, M., Liu, Y., Wang, J., & Geng, D.-F. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.006 · Cited by 34
Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
Roberts, R. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.08.001 · Cited by 31
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 39
Kosmas, C. E., Bousvarou, M. D., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s345072 · Cited by 35
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 34
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 37
Efficacy and safety of mipomersen sodium (Kynamro)
Hovingh, K., Besseling, J., & Kastelein, J. J. P. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793670 · Cited by 33
Luister, A., Schött, H.-F., Husche, C., Schäfers, H., Böhm, M., Plat, J., Gräber, S., Lütjohann, D., Laufs, U., & Weingärtner, O. (2015) · Steroids · doi:10.1016/j.steroids.2015.03.011 · Cited by 33
Green, P., Neely, D., Humphries, S. E., Saunders, T., Gray, V., Gordon, L., Payne, J., Carter, S., Neuwirth, C. K. Y., Rees, A., et al. (2015) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12481 · Cited by 32
Plant Stanol Esters Reduce LDL (Low-Density Lipoprotein) Aggregation by Altering LDL Surface Lipids
Ruuth, M. K., Äikäs, L., Tigistu‐Sahle, F., Käkelä, R., Lindholm, H. J., Simonen, P. P., Kovanen, P. T., Gylling, H., & Öörni, K. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314329 · Cited by 32
Cumulative burden of lipid profiles predict future incidence of ischaemic stroke and residual risk
Dai, L., Xu, J., Zhang, Y., Wang, A., Chen, Z., Mo, J., Li, H., Meng, X., Wu, S., & Wang, Y. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000726 · Cited by 33
Talic, S., Marquina, C., Ofori‐Asenso, R., Petrova, M., Liew, D., Owen, A. J., Lybrand, S., Thomson, D., Ilomäki, J., Zomer, E., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07199-7 · Cited by 34
Emerging Risk Factors for Stroke
Hopewell, J. C., & Clarke, R. (2016) · Stroke · doi:10.1161/strokeaha.115.010646 · Cited by 31
Williams, B., Masi, S., Wolf, J., & Schmieder, R. E. (2020) · Cardiology and Therapy · doi:10.1007/s40119-019-00159-1 · Cited by 30
Lima, G. F., Lopes, R. D. O., Mendes, A. B. A., Brazão, S. C., Autran, L. J., Motta, N. A. V., & Brito, F. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173289 · Cited by 31
Ji, M., Du, L., Ma, Z., Xie, J., Huang, Y., Wei, X., Jiang, X., Xu, J., Yin, R. H., Wang, Y., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33780 · Cited by 31
Vascular dysfunction and increased cardiovascular risk in hypospadias
Lucas-Herald, A. K., Montezano, A. C. I., Alves-Lopes, R., Haddow, L., Alimussina, M., O’Toole, S., Flett, M. E., Lee, B., Amjad, S. B., Steven, M. J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac112 · Cited by 34
European guidelines for the treatment of dyslipidaemias: New concepts and future challenges
Pirillo, A., Casula, M., & Catapano, A. L. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106936 · Cited by 38
Predicting sudden cardiac death using common genetic risk variants for coronary artery disease
Hernesniemi, J. A., Lyytikäinen, L., Oksala, N., Seppälä, I., Kleber, M. E., Mononen, N., März, W., Mikkelsson, J., Pessi, T., Louhelainen, A., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv106 · Cited by 31
Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia
Ferreira, A. M., & da Silva, P. M. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0205-0 · Cited by 33
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 32
IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease
Catapano, A. L., & Ference, B. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.008 · Cited by 30
Self-citationHistory of lipidology and lipoprotein apheresis
Julius, U. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.034 · Cited by 30
Cybulska, B., Kłosiewicz−Latoszek, L., Penson, P. E., Nabavi, S. M., Lavie, C. J., & Banach, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.12.008 · Cited by 30
Mendelian Randomization versus Path Models: Making Causal Inferences in Genetic Epidemiology
Ziegler, A., Mwambi, H. G., & König, I. R. (2015) · Human Heredity · doi:10.1159/000381338 · Cited by 32
Causal Effect of Lipids and Lipoproteins on Atherosclerosis
Ference, B. A. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.001 · Cited by 28
Self-citationEffect of anthocyanins on metabolic syndrome through interacting with gut microbiota
Du, L., Ding, X., Tian, Y., Chen, J., & Li, W. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107511 · Cited by 33
Verbeek, R., Boyer, M., Boekholdt, S. M., Hovingh, G. K., Kastelein, J. J. P., Wareham, N. J., Khaw, K., & Arsenault, B. J. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307995 · Cited by 30
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 30
Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives
Pradhan, A. K., Bhandari, M., & Sethi, R. (2020) · Cardiology Research and Practice · doi:10.1155/2020/9815016 · Cited by 30
Gavina, C., Seabra, D., Pardal, M., Afonso-Silva, M., Grangeia, D., Dinis‐Oliveira, R. J., Araujo, F. P., & Taveira‐Gomes, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226825 · Cited by 29
PCSK9 Inhibitors: A Technology Worth Paying For?
Weintraub, W. S., & Gidding, S. S. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0355-y · Cited by 29
Dron, J. S., Patel, A. P., Zhang, Y., Jurgens, S. J., Maamari, D. J., Wang, M., Boerwinkle, E., Morrison, A. C., de Vries, P. S., Fornage, M., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.5271 · Cited by 30
Taking a longer term view of cardiovascular risk: the causal exposure paradigm
Sniderman, A. D., Toth, P. P., Thanassoulis, G., Pencina, M. J., & Furberg, C. D. (2014) · BMJ · doi:10.1136/bmj.g3047 · Cited by 28
mGWAS-Explorer 2.0: Causal Analysis and Interpretation of Metabolite–Phenotype Associations
Chang, L., Zhou, G., & Xia, J. (2023) · Metabolites · doi:10.3390/metabo13070826 · Cited by 29
Horsfall, L., Hardy, R., Wong, A., Kuh, D. J., & Swallow, D. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.028 · Cited by 28
Traditional Chinese medicine for lipid metabolism disorders.
Li, Y., Wang, X., & Shen, Z. (2017) · Europe PMC (PubMed Central) · Cited by 28
Ting, W., Kuo, W., Kuo, C., Yeh, Y., Shen, C.-Y., Chen, Y.-H., Ho, T., Viswanadha, V. P., Chen, Y.-H., & Huang, C. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515002469 · Cited by 28
Durairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0556-0 · Cited by 27
Parhofer, K. G., Aguíar, C., Banach, M., Drexel, H., Gouni‐Berthold, I., de Isla, L. P., Rietzschel, E. R., Zambon, A., & Ray, K. K. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf007 · Cited by 31
An evaluation of alirocumab for the treatment of hypercholesterolemia
Farnier, M. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1111759 · Cited by 27
Bucur, I. G., Claassen, T., & Heskes, T. (2019) · Statistical Methods in Medical Research · doi:10.1177/0962280219851817 · Cited by 30
The Role of Statins in Current Guidelines
Rached, F. H., & Santos, R. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00861-9 · Cited by 30
Severance, L. M., Carter, H. K., Contijoch, F. J., & McVeigh, E. R. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.11.013 · Cited by 28
Tong, T. Y. N., Perez‐Cornago, A., Bradbury, K. E., & Key, T. J. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab192 · Cited by 26
Liu, H., Li, J., Liu, F., Huang, K., Cao, J., Chen, S., Li, H., Shen, C., Hu, D., Huang, J., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad111 · Cited by 26
Temporal trends in lipid screening and therapy among youth from 2002 to 2012
Zachariah, J. P. V., McNeal, C. J., Copeland, L. A., Fang-Hollingsworth, Y., Stock, E. M., Sun, F., Song, J. J., Gregory, S. T., Tom, J. O., Wright, E. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.06.014 · Cited by 27
Packard, C. J., Weintraub, W. S., & Laufs, U. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.03.008 · Cited by 28
Metadata
- Authors
- Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M.
- Affiliations
- Wayne State University (US)
- University of Tennessee Health Science Center (US)
- Detroit Medical Center (US)
- Corresponding author
- Ference, Brian A.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 60
- Issue
- 25
- Pages
- 2631-2639
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W72392028
- Cited by
- 898
- References
- 44
- Citations by year
- 2026: 69 · 2025: 61 · 2024: 65 · 2023: 80 · 2022: 64 · 2021: 69 · 2020: 81 · 2019: 74 · 2018: 55 · 2017: 48 · 2016: 82 · 2015: 67 · 2014: 41 · 2013: 37 · 2012: 2
- FWCI
- 47.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- Medtronic
- NIH
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- LDL cholesterol, coronary heart disease risk, genetic polymorphism, Mendelian randomization, statin therapy, LDL cholesterol lowering, cardiovascular risk reduction
- MeSH terms
- Coronary Artery Disease, Follow-Up Studies, Genetic Markers, Humans, Cholesterol, LDL, Polymorphism, Genetic, Risk Factors, Time Factors, Global Health, Incidence, Risk Assessment, Genetic Predisposition to Disease, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
